Search Results

Cambrex, a leading global contract development and manufacturing organization, announced that it is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule.

Cambrex, a leading global contract development and manufacturing organization, has completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.

Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina.

Cambrex announced that Snapdragon Chemistry has completed the second phase of its 51,000 square foot expansion in Waltham, Massachusetts.

Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry.

Cambrex celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.

Cambrex today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.